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Abstract 
Objectives 
The ScHARR Bowel Cancer Screening Model has been used to make decisions about 
screening strategies in England. The objective of this study was to perform external 
validation of the ScHARR model against long-term follow-up data about colorectal cancer 
(CRC) incidence and mortality reductions due to screening, from the Nottingham Trial of 
guaiac Faecal Occult Blood Testing for CRC, and the UK Flexible Sigmoidoscopy Screening 
Trial. 
Methods 
The ScHARR model was adapted prior to validation to reflect the setting of each trial in 
terms of population characteristics, details of screening and surveillance programmes, uptake 
of screening and further investigations and study follow-up. The impact of using current 
versus historical CRC incidence and mortality data in the validation was also examined by 
carrying out a series of analyses in which historical data from different years was included in 
the model. 
Results 
The ScHARR model was able to predict CRC incidence and mortality rate/hazard ratios from 
both trials to well within the 95% confidence intervals in the observed data. Whilst it was less 
accurate in predicting absolute incidence and mortality rates, modelling historical incidence 
and mortality data enabled these predictions to be improved considerably. 
Conclusions 
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The ScHARR model is able to replicate the long-term relative benefit from screening 
observed in two large-scale UK based screening trials and can therefore be considered to be 
an appropriate tool to facilitate decision making around the English bowel cancer screening 
programme.  
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Highlights 
x ISPOR guidelines indicate that model credibility depends upon their external 
validation. The ScHARR Bowel Cancer Screening Model has been used to make 
decisions about screening in England, but its external validity has not previously been 
demonstrated. 
x The ScHARR model closely predicts colorectal cancer incidence and mortality hazard 
ratios from two screening trials; the Nottingham Trial of guaiac Faecal Occult Blood 
Testing and the UK Flexible Sigmoidoscopy Screening Trial.  
x Accuracy of predictions is improved if model parameters are adjusted to reflect 
historical changes in colorectal cancer incidence and mortality that have occurred 
since the trials were carried out.   
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Introduction 
Screening for colorectal cancer (CRC) in England has been carried out over the past decade 
through the NHS Bowel Cancer Screening Programme (BCSP) 1. Decisions around which 
screening strategies to implement have been informed by analyses using the ScHARR Bowel 
Cancer Screening Model. This is a cohort state transition model built in Excel that models the 
life experience of a cohort of individuals aged 30 from the general population of England, 
starting with normal epithelium, through to the development of adenomas, CRC and 
subsequent death (see supplementary material for further details). The cohort can undergo a 
vast variety of different CRC screening strategies, or no screening, according to pre-specified 
inputs  2,3. Whilst much of the model can be populated using estimates from published data, 
cancer natural history and screening test characteristics are unobservable processes that 
cannot be modelled directly and instead require model calibration to select parameters that 
produce model predictions fitting the observed outcomes (see Whyte et al., 2011 4).  
The credibility of a model depends upon it having undergone a thorough process of 
verification and validation, to minimise errors and ensure that the model reflects reality 
sufficiently to enable decision making 5. This is particularly important where calibration has 
been carried out to estimate unknown parameters. The International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) guidelines on model transparency and 
validation state that there are five main types of validation that should be considered; face 
validity, internal validity, cross validity, external validity and predictive validity 6. The 
ScHARR model has undergone an extensive process of internal validation as part of model 
development, whilst reviewing of model results by clinical experts has ensured their face 
validity. Cross validity has also been assessed as part of a recent project 3, through 
comparative analysis of results from the ScHARR model with those from a model built 
8 
 
independently by researchers from Oxford University 7. All these processes are helpful for 
identifying errors, but do not assess how accurately the model can represent novel scenarios.  
Data is now available for external validation of the ScHARR model. Over the past few years, 
long-term outcomes for CRC incidence and mortality from two large-scale UK CRC 
screening trials have been published; the Nottingham Trial of guaiac Faecal Occult Blood 
Testing (gFOBT) for CRC (20 year follow-up)8; and the UK Flexible Sigmoidoscopy 
Screening Trial (UKFSST) (11 and 17 year follow-up) 9,10. The Nottingham gFOBT trial was 
conducted between 1981 and 1995 and randomised 152,850 individuals aged between 45 and 
74 years to either biennial gFOBT screening or to control (no screening) groups 11, whilst the 
UKFSST randomised 170,432 individuals aged between 55 and 65 to one-off flexible 
sigmoidoscopy (FS) or to control, and took place between 1994 and 1999 10. Long-term 
follow-up of between 11 and 20 years indicates that both gFOBT and FS screening result in 
significant CRC mortality reductions, but that only FS screening has a significant impact in 
reducing CRC incidence.  
In this analysis we show that the ScHARR model can successfully predict the results of long-
term follow-up of the Nottingham gFOBT trial and the UKFSST, in particular the relative 
benefits of screening compared to no screening. We also demonstrate how the accuracy of 
model predictions is affected if model inputs that are known to have changed over time such 
as CRC incidence and mortality rates, and other cause mortality are adjusted before 
validation to reflect as closely as possible the historical situation in which the trial was 
conducted.  
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Methods 
The background to the ScHARR model is summarised in the supplementary information and 
described in detail elsewhere 3. In brief, it consists of a natural history model with 13 health 
states relating to normal epithelium, low risk adenoma, high risk adenoma, CRC (4 stages, 
clinical and preclinical) and death (from CRC and other causes) (supplementary Figure S1). 
Parameters for natural history transitions and symptomatic diagnosis were calibrated against 
CRC incidence data 12; parameters for mortality were taken from survival data (for CRC 
mortality) and Office for National Statistics (ONS) Life Tables and Death certificate data (for 
other cause mortality) 13-15; parameters for screening sensitivity and specificity were 
calculated using data from the English BCSP 16 combined with model calibrated prevalence, 
whilst other parameters were taken from the BCSP where possible, and from the literature. 
These are summarised in supplementary Table S4.   
In order to improve the success of model validation against the Nottingham gFOBT and 
UKFSST long-term follow-up data 8-10, a series of adaptations to the ScHARR model were 
made in order to reflect the setting of each study as closely as possible. Note that none of 
these changes involved using the long-term follow-up data from either screening study as a 
parameter input or a calibration target, as the aim of the analysis was to externally validate 
the model, not internally validate it. Full explanation of model adaptations and limitations 
with respect to each study can be found in supplementary tables S1 and S2. 
Population: 
CRC incidence and mortality varies by population characteristics including age, gender and 
socioeconomic deprivation 17,18. The model was adapted to reflect the age structure of 
individuals enrolled in the studies as closely as possible; a similar approach has been used for 
validations of other CRC models 19. The cohort-level nature of the model meant that other 
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characteristics from the trials could not be included in the model. However, the gender 
breakdowns reported in both trials were similar to that in the English population, indicating 
that the model would be able to represent an average trial participant in terms of gender. It 
was also not possible to incorporate study exclusion criteria (typically those at high risk of 
disease or with comorbid conditions), which may mean that the modelled population was less 
healthy than the study population 20.   
Previously screened individuals are known to be at lower risk of cancer than those who have 
never been screened 21. Both studies were initiated prior to the implementation of screening 
programmes in England, therefore it was assumed in the model that no-one had previously 
been screened.  
Screening programme: 
Both studies gave details about the screening programme followed, including invitation and 
test protocol, type of screen performed, type and quality of further investigation for positive 
individuals, number of screening rounds, interval between screening round and age at which 
screening was offered. Screening programme details were modelled as closely as possible, 
but some aspects were not possible to replicate. For example, barium enema was used as an 
alternative follow-up investigation to colonoscopy in some cases in the Nottingham gFOBT 
trial 11, but this was not available within the current structure of the ScHARR model. Another 
complication of the Nottingham gFOBT trial that could not be replicated in the model was 
the modification of the re-invitation protocol eligibility criteria part-way through the study 
(Supplementary Table S1). 
Information about detection rates was given in each study, enabling inference of relative 
sensitivity of the test compared to current screening within the BCSP. Detection rates and 
sensitivity are proportional if the underlying age-specific prevalence of CRC and adenomas is 
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the same. The method used for calculation of sensitivity from detection rates is described in 
more detail in the supplementary information. Detection rates in the UKFSS trial were higher 
than those currently seen within the BCSP for FS screening 1,22, so model sensitivity for FS 
(originally derived in the model through calibration against BCSP data) was increased 
proportionally as shown in supplementary Table S3. 
Uptake and completion of screening and subsequent investigations: 
Screening uptake was modified to reflect the information reported in each study. No 
information was given in the studies about uptake of further investigations following a 
positive test, so default values based on English BCSP data were used. Whilst uptake of 
screening and uptake of further investigations in those who test positive is known to vary by 
screening round, screening history and by personal characteristics 23-25; and the Nottingham 
gFOBT trial did give information about uptake by screening round 11, this could not be 
incorporated within the structure of the model. 
Surveillance: 
Both studies indicated that individuals received surveillance following polypectomy, however 
no details were given relating to the criteria for being offered surveillance, stopping 
surveillance, or the surveillance method or frequency. It was therefore assumed that 
surveillance followed the current UK guidelines (see supplementary information for details). 
Length of study follow-up: 
Study follow-up varied between individuals enrolled in the studies, however it was not 
possible to incorporate this within the cohort structure of the model. Mean study follow-up 
time was therefore modelled for each study. 
Historical and geographical setting: 
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Data such as other-cause mortality, CRC mortality and CRC incidence vary significantly over 
time and between different geographical settings. For example, current day CRC and all-
cause mortality in the UK is much lower than it was historically 26, presumably due to 
advances in treatment and early diagnosis through screening. Historical life tables and death 
certificate data are available from the ONS 13,14, whilst CRUK has information about changes 
in age-standardised CRC incidence and mortality over time 26. This was used to calculate 
incidence and mortality multipliers that were applied to the transition from normal epithelium 
to low risk adenoma in the model, in order to represent CRC incidence and mortality at 
historical time periods. This is described in more detail in the supplementary information. 
The Nottingham gFOBT trial took place between 1981 and 1995 8. The impact of using 
current versus historical data in the model was tested by carrying out a series of analyses in 
which historical life tables and death certificate data, together with incidence and mortality 
multipliers from different years was used where available, to represent either current data, 
data from 1981 (the start of the trial), from 1995 (end of the screening period), or from 2005 
(half-way between the end of the screening period and follow-up). 
The UKFSS trial was carried out between 1996 and 1999 with follow-up outcomes published 
in 2010 and 2017 9,10. The impact of using current versus historical data was tested by 
carrying out a series of analyses in which historical life tables and death certificate data, 
together with incidence and mortality multipliers from different years was used where 
available, to represent either current data, data from 1996 (the start of the trial); from 2003 
(halfway between the trial start and first follow-up), or from 2010 (first follow-up date). 
Outcomes: 
The model was run deterministically in order to provide estimates of study outcomes. For all 
analyses, model performance was validated against both relative outcomes (measured as 
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hazard ratios or rate ratios) and absolute outcomes (measured as rates per 100,000 person 
years). For the comparison against the UKFSST, validation against long-term data for both 
published time-points (11 years and 17 years) was carried out. In the basecase analyses, no 
changes were made to incidence and mortality data, and for the Nottingham trial validation it 
was assumed that 4 screening episodes were carried out. Deterministic sensitivity analysis 
was used to examine the impact of modelling historical incidence and mortality as described 
above, and to examine the impact of modelling either 3 or 5 screening episodes for the 
Nottingham trial validation. 
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Results 
Validation against the Nottingham gFOBT trial  
The Nottingham gFOBT trial 20 year follow-up analysis reported a significant reduction in 
certified CRC mortality following gFOBT screening compared to no screening, with a rate 
ratio of 0.91 (95% CI: 0.84 to 0.98) 8 (Table 1). A reduction in CRC incidence was also 
observed, with a rate ratio of 0.97 (95% CI: 0.91 to 1.03), but this was not significant. Using 
current day incidence and mortality data, and assuming four screening episodes per person 
(the basecase scenario), the model is able to replicate this reduction in CRC mortality due to 
gFOBT screening very accurately, but estimates a higher reduction in CRC incidence than 
observed in the trial, although results are well within the reported 95% confidence interval. 
Sensitivity analysis indicates that if the number of screening episodes is reduced to three per 
person, CRC incidence and mortality are slightly higher in the screening arm, whereas if the 
number of screening episodes is increased to five per person, CRC incidence and mortality 
are slightly reduced. 
Whilst the model can accurately replicate rate ratios, absolute incidence and mortality rates 
are poorly replicated by the model using current day incidence and mortality data. The model 
tends to overestimate CRC incidence in both the control and screening arms by about 13%, 
but underestimate absolute CRC and all-cause mortality rates by up to one third (Table 1). 
These differences are corrected in the sensitivity analyses that use historical incidence and 
mortality data, with the results suggesting that absolute CRC incidence rate and absolute all-
cause mortality in the Nottingham gFOBT trial might be best estimated using data from a 
period between 1981 and 1995, and absolute CRC mortality best estimated using data from a 
period between 1995 and 2005, to reflect increased mortality rates and reduced incidence of 
CRC in the past.  
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However, use of historical data does not appear to improve the estimate of the incidence and 
mortality rate ratios. Use of historical data results in overestimation of CRC mortality rate 
ratios, with the poorest estimates coming from the model using the oldest data (albeit still 
within 95% confidence intervals). It is important to note that the trial CRC mortality rates 
shown in Table 1 represent certified CRC mortality, whereas reported verified CRC mortality 
rates were higher (100 per 100,000 person years in the control arm and 91 per 100,000 person 
years in the screening arm). It is unclear which type of mortality rate is best represented by 
the model output as the model uses both death certificate (certified) and survival (verified) 
data.  
Comparison of cumulative CRC incidence and mortality over time in the trial and in the 
model (using 1995 incidence and mortality data) is shown in Figure 1. The incidence curves 
indicate that the model is closely representing the increase in CRC incidence seen in the first 
few years following screening initiation. Cumulative CRC incidence starts to be reduced in 
the screening arm compared to the control arm at around 10 years following screening 
initiation in the model, whilst this appears to take place somewhere between year 7 and year 
15 in the trial. The mortality curves indicate that in the trial, CRC mortality is reduced within 
3-4 years of initiating screening compared to the control arm. However, this is not apparent in 
the model, where the two curves do not start to separate until after year 10. Unlike the trial, 
the model also predicts slightly higher CRC mortality in the screening arm in the years 
following screening initiation in all analyses undertaken (Figure 1 and data not shown).  
Validation against the UKFSST  
The UKFSST follow-up analysis reported a significant reduction in both CRC incidence and 
certified CRC mortality following FS screening compared to no screening, at both 11 and 17 
year time-points 9,10. The data suggests that CRC incidence reductions continue to accumulate 
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slightly beyond 11 years (hazard ratio at 11 years = 0.77 [95% CI: 0.70-0.84]; hazard ratio at 
17 years = 0.74 [95% CI: 0.70-0.80]), whilst mortality reductions stay roughly constant 
between the two time points (HR at 11 years = 0.69 [95% CI: 0.59-0.82]; HR at 17 years = 
0.70 [95% CI: 0.62-0.79]). Using current day incidence and mortality data (basecase 
scenario), these hazard ratios are replicated well within 95% confidence intervals using the 
model (Table 2). Whilst data from other time points is not available from the trial, the model 
predicts that the incidence reduction in the screening arm compared to the control arm peaks 
at 15 years following screening, whilst the CRC mortality reduction peaks at 16 years post 
screening (Figure 2). Absolute incidence and mortality rates per 100,000 person years are 
replicated reasonably well by the model using current day incidence and mortality data, with 
estimates for both tending to be slightly lower than observed data (Table 2). Use of historical 
incidence and mortality data in sensitivity analysis reduces the accuracy of model absolute 
incidence estimates for all modelled years, whilst CRC and all-cause absolute mortality 
estimates are too high using the oldest data and too low using the most recent data, 
suggesting using data from a period between 2003 and 2010 might produce the best 
estimates. Incidence has not substantially changed since the mid1990s when the UKFSST 
was initiated, which is likely to explain the lack of improvements produced through using 
historical incidence data. 
Comparison of cumulative CRC incidence and mortality over time in the trial and in the 
model (using current day incidence and mortality data) is shown in Figure 3. The incidence 
curves indicate that the model is closely representing the increase in CRC incidence seen in 
the first few years following screening initiation. Cumulative CRC incidence starts to be 
reduced in the screening arm compared to the control arm at around six years following 
screening initiation in the model, whilst this appears to take place at year five in the trial. The 
mortality curves indicate that in the trial, CRC mortality is reduced soon after initiating 
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screening compared to the control arm. However, this is not apparent in the model, where the 
two curves do not start to separate until after year five. In common with the Nottingham 
gFOBT trial validation, the model predicts slightly higher CRC mortality in the screening 
arm in the early years following screening initiation in all analyses undertaken (Figure 3 and 
data not shown).   
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Discussion 
Validation of models against external data is essential to ensure their credibility for decision 
making; however, considerable model adaptation may be required before a model can 
accurately replicate trial data. The analyses presented here indicate that following model 
adaptation, the ScHARR model is able to replicate the long-term relative benefit from 
screening observed in two large-scale UK based screening trials, with a level of accuracy that 
falls well within trial 95% confidence intervals 8-10. Interestingly, the model is less able to 
replicate trial data for absolute mortality and incidence rates than it is for relative rates. 
However, the results suggest that this can be improved somewhat by approximating historical 
mortality and incidence data in the model, particularly for the Nottingham gFOBT trial that 
started in 1981, when both incidence and mortality were quite different from today. This 
shows that it is important to build the ability to use historical data into the model if accurate 
validation against long-term data is to be performed. It also implies that estimation of the 
effects of future screening programmes could potentially be made more accurate through 
projection of incidence and mortality trends into the future. Implementing the ability to 
include incidence and mortality data that vary over time would therefore improve the 
ScHARR model, both for validation and for model predictions. 
There are limitations to accurate modelling of historical data that were encountered as part of 
this project. In particular, the lack of detailed historical CRC incidence and survival data by 
age and stage represent a general problem for model validation and prediction. The problem 
was overcome in this analysis by using mortality and incidence multipliers. For simplicity, 
incidence multipliers were applied on the first transition from normal epithelium to low risk 
adenoma. However, there is no evidence that the general increase in CRC incidence over time 
is due to a higher rate of this transition, and it is more likely that all transitions between 
health states show some historical variation. Applying the multiplier at this point implies that 
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incidence of adenomas has also increased over time, and therefore that screening may be of 
more benefit. A further limitation of this approach is that it ignores any differences in age or 
stage distribution of incidence and mortality between historical and current data. This could 
impact on the ability of the model to replicate trial data and therefore to be successfully 
validated if for example stage distribution at diagnosis has shifted significantly to earlier 
stages recently. The introduction of screening has also skewed incidence data over the past 
decade for the screening eligible age group, meaning that underlying changes in incidence 
that may have happened since screening began (e.g. due to changing lifestyles) cannot be 
captured. 
Aside from the problems in using historical data, there are several other limitations that were 
encountered. Firstly, study populations often do not resemble the screened general population 
due to exclusion from participation of individuals with serious illnesses or at high risk of 
CRC due to symptoms or family history. This is likely to result in a trial population being 
healthier than the general population in a way that is not easily represented in a model, 
therefore having lower CRC incidence and mortality than expected, and be less likely to 
benefit from screening (called the healthy volunteer effect) 20. It was reported by Atkin et al., 
(2010) that CRC incidence in the study control group was almost exactly as expected in the 
general population 10, but an equivalent comparison for CRC mortality was not given. 
Secondly, there may be complexities within trial screening pathways that a model cannot 
capture without significant restructuring. For example, individuals in the Nottingham gFOBT 
trial originally did not receive subsequent invitations to screening if they had not attended the 
first screening round ± but this was later changed 11. The model however assumes that 
everyone is re-invited for every eligible screening round. We now know from BCSP data that 
those who have not previously attended screening have a higher incidence of CRC and polyps 
than those who have previously attended screening 21, so this change in screening programme 
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would have impacted study results, although the magnitude of effect when compared with 
model results is likely to be small given a fixed number of screening episodes. Thirdly, in the 
past 35 years, colonoscopy quality is likely to have improved 27, potentially leading to greater 
detection and more successful removal of adenomas. All of these reasons could lead to 
overestimation of screening effectiveness.  
Differences in model predictions and long-term follow-up data can be caused by structural 
model assumptions, which can highlight areas for future model improvements. For example, 
the tendency of the ScHARR model to underestimate CRC mortality reductions, particularly 
in the first couple of years, may be partly due to model assumptions that survival of screen-
detected cancers by stage is identical to survival following opportunistic detection of cancer. 
In fact, recent data suggests that survival is much higher for screen-detected cancers, which 
cannot be entirely explained by the shift towards earlier stage at diagnosis 28,29. The 
availability of detailed differential stage and age specific survival data for cancers detected 
through different diagnostic pathways will allow model predictions to be improved 
considerably. 
Validation of CRC models against 11 year follow-up data from the UKFSST has previously 
been carried out by members of the Cancer Intervention and Surveillance Modelling Network 
(CISNET) 30, through which three independent CRC microsimulation models have been 
developed 31-33, each quite different structurally to the ScHARR model. In common with the 
ScHARR model, all three models underestimated CRC mortality reductions, whilst incidence 
reductions were underestimated by two models (one outside of 95% confidence intervals) and 
overestimated by the other 19. Of all four models, the ScHARR model provides the closest 
estimates of incidence reduction and the second closest for CRC mortality reduction. This is 
likely to be due to the UK focus of the ScHARR model and the careful consideration around 
which adaptations should be carried out to attempt to reproduce the study setting.  
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Conclusion 
The ScHARR model is able to replicate the long-term relative benefit from screening 
observed in two large-scale UK based screening trials; the Nottingham gFOBT trial and the 
UKFSST, with a level of accuracy that falls well within trial 95% confidence intervals. 
Accuracy of predictions is improved if model parameters are adjusted to reflect historical 
changes in colorectal cancer incidence and mortality that have occurred since the trials were 
carried out. Overall, this analysis indicates that the ScHARR Bowel Cancer Screening Model 
is an appropriate tool to facilitate decision making around the NHS BCSP. 
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Table 1: Validation of the ScHARR Bowel Cancer Screening Model against the 20 year 
follow-up of the Nottingham gFOBT trial 8 showing absolute rates per 100,000 person years 
and rate ratios for gFOBT screening versus no screening, using either current-day or 
historical CRC incidence, CRC mortality and all-cause mortality data in the model. For 
current-day results, the impact of altering the number of screening episodes (SE) between 3 
and 5 per person is also shown.  
 CRC Incidence CRC Mortality All-Cause Mortality 
Control Screening Control Screening Control Screening 
Trial  182 176 88 80 3,130 3,140 
Rate ratio (95% CI) 0.97 (0.91-1.03) 0.91 (0.84-0.98) 1.00 (0.99-1.02) 
Model: Current: 4 SE 207 196 72 64 2,088 2,076 
Rate ratio 0.95 0.91 1.00 
Model: Current: 3 SE 207 198 72 66 2,088 2,078 
Rate ratio 0.96 0.92 1.00 
Model: Current: 5 SE 207 194 72 63 2,088 2,075 
Rate ratio 0.94 0.89 1.00 
Model: 1981: 4 SE 174 165 93 88 3,576 3,566 
Rate ratio 0.95 0.95 1.00 
Model: 1995: 4 SE 195 185 93 87 3,012 3,001 
Rate ratio 0.95 0.94 1.00 
Model: 2005: 4 SE 204 193 80 73 2,457 2,445 
Rate ratio 0.95 0.92 1.00 
CRC =  colorectal cancer; CI = confidence interval; SE = screening episodes 
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Table 2: Validation of the ScHARR Bowel Cancer Screening Model against the UKFSS trial 
9,10
 showing absolute rates per 100,000 person years and hazard ratios for FS screening versus 
no screening, using either current-day or historical CRC incidence, CRC mortality and all-
cause mortality data in the model, at either 11 years or 17 years. 
 CRC Incidence CRC Mortality All-Cause Mortality 
Control Screening Control Screening Control Screening 
11 Year Follow-up 
Trial  149 114 44 30 1,124 1,093 
Hazard ratio (95% 
CI) 
0.77 (0.70-0.84) 0.69 (0.59-0.82) 0.97 (0.94-1.00) 
Model: Current 
Day 
145 112 38 28 917 902 
Hazard ratio 0.77 0.73 0.98 
Model: 1996 139 108 51 42 1,488 1,475 
Hazard ratio 0.78 0.82 0.99 
Model: 2003 139 108 45 36 1,201 1,188 
Hazard ratio 0.78 0.79 0.99 
Model: 2010 145 112 37 26 976 962 
Hazard ratio 0.77 0.72 0.99 
17 Year Follow-up 
Trial  184 137 56 39 1,483 1,472 
Hazard ratio (95% 
CI) 
0.74 (0.70-0.80) 0.70 (0.62-0.79) 0.99 (0.97-1.01) 
24 
 
Model: Current 
Day 
179 136 53 37 1,309 1,289 
Hazard ratio 0.76 0.69 0.98 
Model: 1996 169 129 69 52 2,116 2,095 
Hazard ratio 0.76 0.75 0.99 
Model: 2003 171 130 62 45 1,732 1,712 
Hazard ratio 0.76 0.73 0.99 
Model: 2010 178 136 51 35 1,394 1,374 
Hazard ratio 0.76 0.68 0.99 
CRC =  colorectal cancer; CI = confidence interval  
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Figure 1: Estimates of cumulative colorectal cancer (CRC) incidence (top) and mortality 
(bottom) for gFOBT screening versus no screening from the Nottingham gFOBT trial study 8 
(solid lines) and the model (dashed lines) using 1995 incidence and mortality data with 20 
years of follow-up from first screen. 
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Figure 2: Model projected hazard ratios for every year of a lifetime horizon for FS screening 
versus no screening using current day incidence and mortality data. Observed data from the 
UK Flexible Sigmoidoscopy Screening Trial (UKFSST) 9 is plotted as point estimates with 
error bars indicating 95% confidence intervals. The graph indicates that peak mortality 
reductions in the screening arm would be expected 16 years post screening, whilst peak 
reduction in incidence would be expected to occur 15 years after screening (dotted vertical 
lines). 
 
  
27 
 
Figure 3: Estimates of cumulative colorectal cancer (CRC) incidence (top) and mortality 
(bottom) for flexible sigmoidoscopy (FS) screening versus no screening from the UK 
Flexible Sigmoidoscopy Screening Trial (UKFSST) 9 and the model using current day 
incidence and mortality data with 17 years of follow-up from baseline screen. 
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